NKTR SEC-arkiveringar - Nektar Therapeutics- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

LEI	5299005I24806IOIYE03
CIK	906709

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nektar Therapeutics

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

May 8, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 Nektar Therapeutics ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 Nektar Therapeutics (Exact name of Registrant as Specified in Its Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numb
May 8, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 NEKTAR THERAPEUTICS Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0.
May 8, 2026	EX-1.1	NEKTAR THERAPEUTICS EQUITY DISTRIBUTION AGREEMENT EX-1.1 Exhibit 1.1 NEKTAR THERAPEUTICS EQUITY DISTRIBUTION AGREEMENT May 8, 2026 GUGGENHEIM SECURITIES, LLC 330 Madison Avenue New York, NY 10017 H.C. WAINWRIGHT & CO., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Nektar Therapeutics, a company organized under the laws of Delaware (the “Company”), proposes to issue and sell
May 8, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK
May 8, 2026	424B5	Nektar Therapeutics Up to $150,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-291466 PROSPECTUS SUPPLEMENT (To Prospectus Dated November 12, 2025) Nektar Therapeutics Up to $150,000,000 Common Stock We have entered into an equity distribution agreement, or the Equity Distribution Agreement, with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC, or the sales agents, relating to shares of o
May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2026 NEKTAR THERAPEUTICS ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 7, 2026	EX-99.1	Nektar Therapeutics Reports First Quarter 2026 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2026 Financial Results SAN FRANCISCO, May 7, 2026 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025. Nektar’s cash and marketable se
April 24, 2026	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
April 24, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 24, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 23, 2026	EX-1.1	3,532,609 Shares of Common Stock NEKTAR THERAPEUTICS UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 3,532,609 Shares of Common Stock NEKTAR THERAPEUTICS UNDERWRITING AGREEMENT April 21, 2026 JEFFERIES LLC TD SECURITIES (USA) LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TD SECURITIES (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 c/o PIPER SANDLER & CO. 350 North 5th Street, Suit
April 23, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 NEKTAR THERAPEUTICS Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0.
April 23, 2026	EX-99.1	Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering EX-99.1 Exhibit 99.1 Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering SAN FRANCISCO, April 21, 2026 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million of shares o
April 23, 2026	424B5	3,532,609 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-291466 Prospectus Supplement (To Prospectus Dated November 12, 2025) 3,532,609 Shares of Common Stock We are offering 3,532,609 shares of our common stock, par value $0.0001 per share, or common stock, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Capital
April 23, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2026 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 20, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2026 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 20, 2026	424B5	Subject to completion, dated April 20, 2026 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-291466 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
April 20, 2026	EX-99.2	Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, exp EX-99.2 Exhibit 99.2 Phase 2b REZOLVE-AA 52-Week Topline Results: 16-Week Extension Treatment Period Rezpegaldesleukin in Patients with Severe-to-Very-Severe Alopecia Areata April 20, 2026 Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1
April 20, 2026	EX-99.1	52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with 29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieve EX-99.1 Exhibit 99.1 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin 29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatment Increasing proportions of p
April 20, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2026 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 13, 2026	EX-97	Nektar Therapeutics COMPENSATION RECOVERY POLICY Adopted as of June 8, 2023 Exhibit 97 Nektar Therapeutics COMPENSATION RECOVERY POLICY Adopted as of June 8, 2023 Nektar Therapeutics, a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below.
March 13, 2026	EX-21.1	Subsidiaries of Nektar Therapeutics Exhibit 21.1 Subsidiaries of Nektar Therapeutics None.
March 13, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
March 13, 2026	EX-19.1	You are responsible for ensuring compliance with this Policy by all of your Affiliates. In the event that you leave the Company for any reason, this Security Trading Policy will continue to apply to you and your Affiliates until the later of: (1) the Exhibit 19.1 NEKTAR THERAPEUTICS SECURITY TRADING POLICY Nektar Therapeutics (“Nektar” or the “Company”) is committed to complying with all applicable laws and regulations. Nektar has adopted this Security Trading Policy (“Policy”) to prohibit Affiliates from trading in the securities of any company, including Nektar, while in possession of material, non-public information about such company, as w
March 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2026 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 12, 2026	EX-99.1	Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results SAN FRANCISCO, Mar 12, 2026 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in marketable securities on December 31, 2025 were $245.8 million as compared to $269.1 million on December 31, 2024. Cash and
February 13, 2026	EX-99.1	Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering EX-99.1 Exhibit 99.1 Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering SAN FRANCISCO, February 11, 2026 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $400 million of share
February 13, 2026	424B5	6,603,449 Shares of Common Stock Pre-Funded Warrants to Purchase up to 293,103 Shares of Common Stock 293,103 Shares of Common Stock Underlying the Pre-Funded Warrants 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-291466 Prospectus Supplement (To Prospectus Dated November 12, 2025) 6,603,449 Shares of Common Stock Pre-Funded Warrants to Purchase up to 293,103 Shares of Common Stock 293,103 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 6,603,449 shares of our common stock, par value $0.0001 per share, or
February 13, 2026	EX-1.1	6,603,449 Shares of Common Stock Pre-Funded Warrants to Purchase 293,103 Shares of Common Stock NEKTAR THERAPEUTICS UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 6,603,449 Shares of Common Stock and Pre-Funded Warrants to Purchase 293,103 Shares of Common Stock NEKTAR THERAPEUTICS UNDERWRITING AGREEMENT February 11, 2026 JEFFERIES LLC TD SECURITIES (USA) LLC PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o TD SECURITIES (USA) LLC 1 Vanderbilt Avenue New Y
February 13, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 NEKTAR THERAPEUTICS Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0.
February 13, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2026 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 13, 2026	EX-4.1	Form of Pre-Funded Warrant NEKTAR THERAPEUTICS WARRANT TO PURCHASE COMMON STOCK EX-4.1 Exhibit 4.1 Form of Pre-Funded Warrant NEKTAR THERAPEUTICS WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: February [], 2026 Nektar Therapeutics, a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registere
February 10, 2026	EX-99.1	New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing 71% and 83% of patients maintained EASI-75 responses and 8 EX-99.1 Exhibit 99.1 New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing 71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in re
February 10, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2026 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 10, 2026	424B5	Subject to completion, dated February 10, 2026 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-291466 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
February 10, 2026	EX-99.2	Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, exp EX-99.2 Phase 2b REZOLVE-AD: Topline Results from 36-Week Maintenance Period Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis February 10, 2026 Exhibit 99.2 Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, incl
February 10, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2026 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2026 NEKTAR THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2026 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
December 16, 2025	EX-99.1	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28. EX-99.1 Exhibit 99.1 REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo Mean percent reduction in SALT scores at 36 weeks was 30% for both treatment arms
December 16, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2025 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
December 16, 2025	EX-99.2	Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, exp EX-99.2 Exhibit 99.2 Phase 2b REZOLVE-AA Topline Results from 36-Week Induction Treatment Period Rezpegaldesleukin in Patients with Severe-to-Very-Severe Alopecia Areata December 16, 2025 Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 19
November 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2025 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 12, 2025	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 NEKTAR THERAPEUTICS Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0.
November 12, 2025	S-3ASR	As filed with the Securities and Exchange Commission on November 12, 2025 S-3ASR As filed with the Securities and Exchange Commission on November 12, 2025 Registration No.
November 12, 2025	EX-4.8	NEKTAR THERAPEUTICS 2025 INDUCEMENT PLAN Exhibit 4.8 NEKTAR THERAPEUTICS 2025 INDUCEMENT PLAN 1. PURPOSE OF PLAN The purpose of this Nektar Therapeutics 2025 Inducement Plan (this “Plan”) of Nektar Therapeutics, a Delaware corporation (the “Corporation”), is to enable the Corporation and its Subsidiaries (as such term is defined in Section 2) to grant equity awards to induce highly-qualified prospective officers and employees who are not
November 12, 2025	EX-4.2	NEKTAR THERAPEUTICS Dated as of [ ] Senior Debt Securities EX-4.2 Exhibit 4.2 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate
November 12, 2025	424B5	Nektar Therapeutics Up to $110,000,000 Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286222 PROSPECTUS SUPPLEMENT (To Prospectus dated April 1, 2025) Nektar Therapeutics Up to $110,000,000 Common Stock We have entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler & Co. and BTIG, LLC, or the sales agents, relating to shares of our common stock offered by t
November 12, 2025	EX-4.3	NEKTAR THERAPEUTICS Dated as of [ ] Subordinated Debt Securities EX-4.3 Exhibit 4.3 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS3 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certi
November 12, 2025	S-8	As filed with the Securities and Exchange Commission on November 12, 2025 As filed with the Securities and Exchange Commission on November 12, 2025 Registration No.
November 12, 2025	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Nektar Therapeutics Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Nektar Therapeutics Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.
November 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2025 NEKTAR THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
November 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006
November 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2025 NEKTAR THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
November 6, 2025	EX-99.1	Nektar Therapeutics Reports Third Quarter 2025 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2025 Financial Results SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable securities on September 30, 2025 were $270.2 million as compared to $269.1 million on December 31, 2024. Nektar’s cash and marke
September 18, 2025	EX-99.2	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis High dose rezp Exhibit 99.2 Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 Study met primary and key secondary endpoints at week 16 in patients with moderate-to-severe atopic dermatitis High dose rezpegaldesleukin achieved statistical significance on multiple patient-reported outcome assessments at completion of 16-week induction perio
September 18, 2025	EX-99.1	Efficacy and Safety of Rezpegaldesleukin, A Selective Regulatory T - Cell - Inducing Interleukin - 2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from the 16 - Week Induction of a Randomized Phase 2b Study (REZOLVE - AD) Jonathan I Exhibit 99.1 Efficacy and Safety of Rezpegaldesleukin, A Selective Regulatory T - Cell - Inducing Interleukin - 2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from the 16 - Week Induction of a Randomized Phase 2b Study (REZOLVE - AD) Jonathan I. Silverberg 1 , Thomas Bieber 2 , Richard B. Warren 3 , Raj Chovatiya 4,5 , Melinda Gooderham 6 , Spyridon Gkalpakiotis 7 , Adam Reich 8
September 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2025 NEKTAR THERAPE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 18, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File N
September 9, 2025	144	144 144 0001206869 XXXXXXXX LIVE 0000906709 NEKTAR THERAPEUTICS 000-24006 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 ROBIN HOWARD W Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 6666 311204.
September 5, 2025	144	144 144 0001206869 XXXXXXXX LIVE 0000906709 NEKTAR THERAPEUTICS 000-24006 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 ROBIN HOWARD W Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 6666 256837.
September 4, 2025	144	144 144 0001206869 XXXXXXXX LIVE 0000906709 NEKTAR THERAPEUTICS 000-24006 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 ROBIN HOWARD W Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 5166 174119.
September 4, 2025	144	144 144 0001789857 XXXXXXXX LIVE 0000906709 NEKTAR THERAPEUTICS 000-24006 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 Zalevsky Jonathan Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 1721 57688.
September 2, 2025	144	144 144 0001789857 XXXXXXXX LIVE 0000906709 NEKTAR THERAPEUTICS 000-24006 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 Zalevsky Jonathan Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 485 14600.
September 2, 2025	144	144 144 0001206869 XXXXXXXX LIVE 0000906709 NEKTAR THERAPEUTICS 000-24006 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300 ROBIN HOWARD W Officer Director Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 1500 45243.
August 8, 2025	EX-FILING FEES	Filing Fee Table Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 NEKTAR THERAPEUTICS Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, $0.
August 8, 2025	EX-4.8	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended. Exhibit 4.8 NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1. PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this “Plan”) of Nektar Therapeutics, a Delaware corporation (the “Corporation”), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through t
August 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT
August 8, 2025	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) Delaware 94-3134940 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification Number) 455 Mission Bay Boulevard South San Francis
August 7, 2025	EX-99.1	Nektar Therapeutics Reports Second Quarter 2025 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2025 Financial Results SAN FRANCISCO, August 7, 2025 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable securities on June 30, 2025 were $175.9 million as compared to $269.1 million on December 31, 2024. Nektar’s cash and marketable securities at
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 000-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
July 1, 2025	EX-99.1	Nektar Therapeutics Announces Pricing of $100 Million Public Offering EX-99.1 Exhibit 99.1 Nektar Therapeutics Announces Pricing of $100 Million Public Offering SAN FRANCISCO, July 1, 2025 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering of $100 million of shares of its common stock
July 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2025 NEKTAR THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number
July 1, 2025	EX-1.1	Underwriting Agreement, dated June 30, 2025, between Nektar Therapeutics and Jefferies LLC as representative of the several underwriters named therein. EX-1.1 Exhibit 1.1 4,255,320 Shares of Common Stock NEKTAR THERAPEUTICS UNDERWRITING AGREEMENT June 30, 2025 JEFFERIES LLC As Representative of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Nektar Therapeutics, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule
July 1, 2025	424B5	4,255,320 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286222 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 1, 2025) 4,255,320 Shares of Common Stock We are offering 4,255,320 shares of our common stock, par value $0.0001 per share, or common stock, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Capital Market un
June 30, 2025	424B5	Subject to completion, dated June 30, 2025 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286222 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
June 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2025 (June 24, 2025) NEK UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2025 (June 24, 2025) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commis
June 24, 2025	EX-99.1	REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from Exhibit 99.1 REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for key secondary endpoints at week 16 of disea
June 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2025 NEKTAR THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 24, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number
June 24, 2025	EX-99.2	1 Phase 2b REZOLVE - AD Topline Results from 16 - Week Induction Rezpegaldesleukin in Patients with Moderate - to - Severe Atopic Dermatitis June 24, 2025 Forward - Looking Statements 2 Safe Harbor Statement This presentation and any accompanying ora Exhibit 99.2 1 Phase 2b REZOLVE - AD Topline Results from 16 - Week Induction Rezpegaldesleukin in Patients with Moderate - to - Severe Atopic Dermatitis June 24, 2025 Forward - Looking Statements 2 Safe Harbor Statement This presentation and any accompanying oral discussion contains forward - looking statements within the meaning of the Private Sec urities Litigation Reform Act of 1995, including
June 6, 2025	EX-3.2	Certificate of Amendment to the Amended Certificate of Incorporation of Nektar Therapeutics Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED CERTIFICATE OF INCORPORATION OF NEKTAR THERAPEUTICS Nektar Therapeutics (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: This amendment to the Corporation’s Amended Certificate of Incorporation, as amended from time to ti
June 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2025 NEKTAR THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number)
June 6, 2025	EX-3.1	Certificate of Amendment to the Amended Certificate of Incorporation of Nektar Therapeutics Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED CERTIFICATE OF INCORPORATION OF NEKTAR THERAPEUTICS Nektar Therapeutics (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: Effective upon the filing of this amendment to the Corporation’s Amended Certificate of Incorporatio
June 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2025 NEKTAR THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 28, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 27, 2025 (May 23, 2025) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK
May 8, 2025	EX-99.1	Nektar Therapeutics Reports First Quarter 2025 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2025 Financial Results SAN FRANCISCO, May 8, 2025 - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar’s cash and marketable securities are e
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 NEKTAR THERAPEUTICS ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number)
April 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 25, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
April 15, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
April 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2025 (April 3, 2025) NEK UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2025 (April 3, 2025) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commis
March 28, 2025	CORRESP	VIA EDGAR VIA EDGAR March 28, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
March 28, 2025	EX-1.2	Equity Distribution Agreement, by and among the Registrant, Piper Sandler & Co. and BTIG, LLC. Exhibit 1.2 NEKTAR THERAPEUTICS EQUITY DISTRIBUTION AGREEMENT March 28, 2025 PIPER SANDLER & CO. 1251 6th Avenue, 6th Floor New York, NY 10020 BTIG, LLC 65 East 55th Street New York, NY 10022 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Nektar Therapeutics, a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to ti
March 28, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Offering of Securities: Fees to Be Paid Equity Common Stock, par value $0.
March 28, 2025	S-3	As filed with the Securities and Exchange Commission on March 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2025 Registration No.
March 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Nektar Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Nektar Therapeutics (Exact name of Registrant as Specified in Its Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File N
March 28, 2025	EX-4.2	Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.2 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sect
March 28, 2025	EX-4.3	Form of indenture for subordinated debt securities and the related form of subordinated debt security. Exhibit 4.3 NEKTAR THERAPEUTICS Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS3 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate
March 20, 2025	LETTER	LETTER March 20, 2025 Howard Robin Chief Executive Officer Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158 Re: Nektar Therapeutics Draft Registration Statement on Form S-3 Submitted March 14, 2025 CIK No.
March 14, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.
March 14, 2025	S-8	As filed with the Securities and Exchange Commission on March 14, 2025 As filed with the Securities and Exchange Commission on March 14, 2025 Registration No.
March 14, 2025	EX-21.1	Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics None.
March 14, 2025	EX-19.1	Nektar Therapeutics Insider Trading Policy Exhibit 19.1 NEKTAR THERAPEUTICS SECURITY TRADING POLICY Nektar Therapeutics (“Nektar” or the “Company”) is committed to complying with all applicable laws and regulations. Nektar has adopted this Security Trading Policy (“Policy”) to prohibit Affiliates from trading in the securities of any company, including Nektar, while in possession of material, non-public information about such company, as w
March 14, 2025	EX-99	Unaudited Pro Forma Condensed Consolidated Financial Statements for the year ended December 31, 2024 Exhibit 99 Unaudited Pro Forma Condensed Consolidated Financial Statements On December, 2, 2024, Nektar Therapeutics (Nektar, we) completed the sale (the Transaction) of our manufacturing facility located in Huntsville, Alabama (the Facility) and certain other manufacturing assets related thereto, including the assignment of our existing manufacturing and supply obligations, to Gannet BioChem, an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand), via an Asset Purchase Agreement (the APA), for consideration of $64.
March 14, 2025	EX-97	Nektar Therapeutics Compensation Recovery Policy, dated June 8, 2023 Exhibit 97 Nektar Therapeutics COMPENSATION RECOVERY POLICY Adopted as of June 8, 2023 Nektar Therapeutics, a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below.
March 14, 2025	DRS	As confidentially submitted to the Securities and Exchange Commission on March 14, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidentia Table of Contents As confidentially submitted to the Securities and Exchange Commission on March 14, 2025.
March 14, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
March 14, 2025	DRSLTR	Goodwin Procter LLP DRSLTR Goodwin Procter LLP 601 Marshall St. Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 March 14, 2025 CONFIDENTIAL SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Nektar Therapeutics Draft Registration Statement on Form S-3 Ladies and Gentlemen: On behalf of Nektar Therapeutics (the “Company”), w
March 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2025 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 12, 2025	EX-99.1	NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results SAN FRANCISCO, March 12, 2025 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar’
February 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 24, 2025	EX-99.1	Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus -- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- Exhibit 99.1 Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus - TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study - SAN FRANCISCO, CA and New York, NY, February 24, 2025 - Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes researc
February 14, 2025	EX-99	JOINT FILING AGREEMENT Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G dated February 14, 2025 relating to the Common Stock, $0.
February 14, 2025	EX-99	CONTROL PERSON IDENTIFICATION Exhibit B CONTROL PERSON IDENTIFICATION Samlyn Capital, LLC is the relevant entity for which Robert Pohly may be considered a control person.
February 14, 2025	EX-1	EXHIBIT 1 EX-1 2 ex1.htm EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in
February 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 NEKTAR THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
December 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2024 NEKTAR THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 2, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
November 14, 2024	SC 13G	NKTR / Nektar Therapeutics / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 eventidenektar-sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Nektar Therapeutics (Name of Issuer – as specified in its charter) Common Stock, $0.0001 par value (Title of Class of Securities) 640268108 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statemen
November 14, 2024	SC 13G/A	NKTR / Nektar Therapeutics / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-nktr093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 640268108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp
November 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006
November 8, 2024	SC 13G	NKTR / Nektar Therapeutics / BlackRock, Inc. Passive Investment SC 13G 1 us6402681083110824.txt us6402681083110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) NEKTAR THERAPEUTICS - (Name of Issuer) Common Stock - (Title of Class of Securities) 640268108 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box
November 7, 2024	EX-99.1	Nektar Therapeutics Reports Third Quarter 2024 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2024 Financial Results SAN FRANCISCO, November 7, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar’s cash and m
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
November 4, 2024	EX-99.1	MONDAY NOVEMBER 4, 2024 AT 5:30AM PT, 7:30 AM CT Exhibit 99.1 FINAL CONFIDENTIAL PRESS RELEASE FOR ISSUANCE MONDAY NOVEMBER 4, 2024 AT 5:30AM PT, 7:30 AM CT Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama Huntsville-based facility to be spun out as standalone Ampersand portfolio company. Nektar to receive $90 million in total consideration for the b
November 4, 2024	EX-1.1	Asset Purchase Agreement, dated as of November 1, 2024, between Nektar and Purchaser. Exhibit 1.1 Execution Version CONFIDENTIAL ASSET PURCHASE AGREEMENT by and between Nektar Therapeutics and [* * *] Dated as of November 1, 2024 Table of Contents Clause Page 1. Definitions and Terms 1 1.1 Definitions 1 1.2 Other Definitional Provisions 16 2. Purchase and Sale 17 2.1 Purchase and Sale of Assets 17 2.2 Consents 18 2.3 Excluded Assets 19 2.4 Assumption of Certain Obligations 21 2.5 E
November 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2024 NEKTAR THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
October 22, 2024	SC 13G	NKTR / Nektar Therapeutics / BlackRock, Inc. Passive Investment SC 13G 1 us6402681083102224.txt us6402681083102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) NEKTAR THERAPEUTICS - (Name of Issuer) Common Stock - (Title of Class of Securities) 640268108 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT
August 9, 2024	EX-10.1(6)	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended.++ NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1. PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this “Plan”) of Nektar Therapeutics, a Delaware corporation (the “Corporation”), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 8, 2024	EX-99.1	Nektar Therapeutics Reports Second Quarter 2024 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2024 Financial Results SAN FRANCISCO, August 8, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. Nektar’s cash and marketable
June 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2024 (June 5, 2024) NEKTA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2024 (June 5, 2024) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi
June 5, 2024	424B3	Up to 25,000,000 Shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrant Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279760 PROSPECTUS Up to 25,000,000 Shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrant This prospectus relates to the proposed resale or other disposition from time to time by the selling stockholder identified in this prospectus, or the Selling Stockholder, of up to an aggregate of 25,000,000 shares of our
June 3, 2024	CORRESP	VIA EDGAR VIA EDGAR June 3, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 31, 2024	LETTER	LETTER United States securities and exchange commission logo May 31, 2024 Mark Wilson General Counsel Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158 Re: Nektar Therapeutics Registration Statement on Form S-3 Filed May 28, 2024 File No.
May 28, 2024	S-3	As filed with the Securities and Exchange Commission on May 28, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on May 28, 2024 Registration No.
May 28, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Newly Registered Securities Fees to Be Paid Equity Common Stock, par value $0.
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK
May 10, 2024	EX-10.1(6)	Amendment No. 1 to Purchase and Sale Agreement, dated December 16, 2020, by and between entities managed by Healthcare Royalty Management, LLC and Nektar Therapeutics.+ Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT This AMENDMENT NO. 1 TO PURCHASE AND SALE AGREEMENT (this “First Amendment”), dated as of March 4, 2024, is by and among Nektar Therapeutics, a Delaware corporatio
May 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 NEKTAR THERAPEUTICS ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 9, 2024	EX-99.1	Nektar Therapeutics Reports First Quarter 2024 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2024 Financial Results SAN FRANCISCO, May 9, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023. Nektar’s cash and marketable sec
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 26, 2024	ARS	ARS w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
April 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2024 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 15, 2024	SC 13G	NKTR / Nektar Therapeutics / TCG Crossover GP II, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 640268108 (CUSIP Number) March 6, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the
March 15, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d800776dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that
March 5, 2024	EX-97	Nektar Therapeutics Compensation Recovery Policy, dated June 8, 2023 Exhibit 97 Nektar Therapeutics COMPENSATION RECOVERY POLICY Adopted as of June 8, 2023 Nektar Therapeutics, a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below.
March 5, 2024	10-K	w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K Table of Contents w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
March 5, 2024	EX-21.1	Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics None.
March 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 NEKTAR THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number
March 4, 2024	EX-10.1	Securities Purchase Agreement, dated March 4, 2024, by and among the registrant and TCG Crossover Fund II, L.P. (incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed on March 4, 2024). EX-10.1 Exhibit 10.1 NEKTAR THERAPEUTICS SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of March 4, 2024 (the “Effective Date”), by and between NEKTAR THERAPEUTICS, a Delaware corporation (the “Company”), and TCG Crossover Fund II, L.P., a Delaware limited partnership (the “Purchaser”). WHEREAS, the Purchaser desires to purchase, and the Company has a
March 4, 2024	EX-99.1	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results SAN FRANCISCO, March 4, 2024 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in marketable securities at December 31, 2023, were $329.4 million as compared to $505.0 million at December 31,
March 4, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number
March 4, 2024	EX-4.1	Form of Pre-Funded Warrant EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUB
February 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2024 (February 12, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 16, 2024 (February 12, 2024) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation)
February 14, 2024	SC 13G/A	NKTR / Nektar Therapeutics / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2024	SC 13G/A	NKTR / Nektar Therapeutics / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245429d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che
February 14, 2024	SC 13G/A	NKTR / Nektar Therapeutics / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243953d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares”) (Tit
February 14, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 tm245429d14ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio
February 13, 2024	SC 13G/A	NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01524-nektartherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Nektar Therapeutics Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desi
January 10, 2024	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2024 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
November 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2023 (November 24, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2023 (November 24, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation)
November 8, 2023	EX-10.6	Letter Agreement dated as of September 6, 2023 by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+ Exhibit 10.1 Confidential Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and is the type that the registrant treats as private or confidential. Bristol-Myers Squibb Company Route 206 & Province Line Road Princeton, NJ 08543 September 6, 2023 Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158 Attenti
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
November 7, 2023	EX-99.1	Nektar Therapeutics Reports Third Quarter 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2023 Financial Results SAN FRANCISCO, November 7, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in marketable securities at September 30, 2023, were $372.7 million as compared to $505.0 million at December 31, 2022. Nektar’s cash and
September 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2023 (September 6, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2023 (September 6, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation)
August 17, 2023	SC 13G	NKTR / Nektar Therapeutics / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEKTAR THERAPEUTICS (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 640268108 (CUSIP Number) August 07, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
August 14, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.
August 14, 2023	S-8	As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No.
August 9, 2023	EX-10.2	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan, as amended.++ NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1.PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this “Plan”) of Nektar Therapeutics, a Delaware corporation (the “Corporation”), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through the grant of a
August 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT
August 9, 2023	EX-10.1	Employment Separation and Release Agreement effective as of June 19, 2023 by and between Nektar Therapeutics and Jillian B. Thomsen.++ EMPLOYMENT SEPARATION AND RELEASE AGREEMENT This Employment Separation and Release Agreement (“Agreement”) is entered into between Nektar Therapeutics, a Delaware corporation (the “Company”), and JILLIAN B.
August 8, 2023	EX-99.1	Nektar Therapeutics Reports Second Quarter 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2023 Financial Results SAN FRANCISCO, August 8, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in marketable securities at June 30, 2023, were $409.4 million as compared to $505.0 million at December 31, 2022. Nektar’s cash and marketable
August 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 7, 2023	EX-99.2	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company EASI-Related and PASI-Related Clinical Efficacy Endpoints in Ato Exhibit 99.2 Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022 San Francisco, CA, A
August 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 7, 2023	EX-99.1	Slides Titled “Rezpegaldesleukin (REZPEG) Corrected Phase 1b Dataset for Studies of REZPEG in Atopic Dermatitis and Psoriasis” Exhibit 99.1
July 10, 2023	SC 13G/A	NKTR / Nektar Therapeutics / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Nektar Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
July 10, 2023	SC 13G/A	NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Nektar Therapeutics Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: June 30, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Ru
July 7, 2023	SC 13G/A	NKTR / Nektar Therapeutics / BlackRock Inc. Passive Investment us6402681083070723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 19) NEKTAR THERAPEUTICS - (Name of Issuer) Common Stock - (Title of Class of Securities) 640268108 - (CUSIP Number) June 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
July 7, 2023	SC 13G/A	NKTR / Nektar Therapeutics / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* Nektar Therapeutics (Name of Issuer) COM (Title of Class of Securities) 640268108 (CUSIP Number) June 30, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil
July 3, 2023	SC 13G	NKTR / Nektar Therapeutics / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Nektar Therapeutics (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 640268108 (CUSI
July 3, 2023	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Nektar Therapeutics, a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2023 (June 22, 2023) NEK UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2023 (June 22, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commis
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2023 (June 8, 2023) NEKTA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2023 (June 8, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi
June 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2023 (May 26, 2023) NEKTA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2023 (May 26, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi
May 10, 2023	EX-10.1	Consulting Agreement between Nektar Therapeutics and FLG Partners, LLC dated April, 2023++ CONFIDENTIAL CONSULTING AGREEMENT Exhibit 10.1 This Confidential Consulting Agreement (the “Agreement”) is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and Nektar Therapeutics, a Delaware company, with its principal place of business at 455 Mission Bay Boulevard South, Suite 100, San Fr
May 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK
May 9, 2023	EX-99.1	Nektar Therapeutics Reports First Quarter 2023 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2023 Financial Results SAN FRANCISCO, May 9, 2023 /PRNewswire/ – Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in marketable securities at March 31, 2023, were $456.8 million as compared to $505.0 million at December 31, 2022. Nektar’s cash and marketable se
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 NEKTAR THERAPEUTICS ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 5, 2023	SC 13G/A	NKTR / Nektar Therapeutics / BlackRock Inc. Passive Investment us6402681083050423.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 18) NEKTAR THERAPEUTICS - (Name of Issuer) Common Stock - (Title of Class of Securities) 640268108 - (CUSIP Number) April 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 27, 2023	EX-99.1	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development Company plans to move REZPEG forward into Phase 2 clinical st Exhibit 99.1 Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development Company plans to move REZPEG forward into Phase 2 clinical study in atopic dermatitis SAN FRANCISCO, April 27, 2023 - Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the
April 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2023 (April 23, 2023) N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2023 (April 23, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Comm
April 17, 2023	EX-99.1	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan -- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in diffuse large B- Exhibit 99.1 Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan - Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs - - Development of NKTR-255 in diffuse large B-cell lymphoma and bladder cancer to continue as strategic partnering options are pursued - - Cost restructuring plan reduces San Francisco-b
April 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2023 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 14, 2023	SC 13G	NKTR / Nektar Therapeutics / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
April 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2023 (April 6, 2023) NE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2023 (April 6, 2023) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commi
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2023 NEKTAR THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 13, 2023	EX-99.1	Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank Exhibit 99.1 Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank SAN FRANCISCO, March 11, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today issued a statement confirming that it does not have any accounts at Silicon Valley Bank, and it does not hold any cash deposits or securities at Silicon Valley Bank. At Decembe
February 28, 2023	EX-99.1	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results SAN FRANCISCO, Feb. 28, 2023 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022. Cash and investments in marketable securities at December 31, 2022, were approximately $505.0 million as compared to $798.8 million at
February 28, 2023	EX-21.1	Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics None.
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ___________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For th Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
February 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 NEKTAR THERAPEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 23, 2023	EX-99.2	Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint Clinically meaningful Exhibit 99.2 Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus Improvement in SLEDAI-2K score observed as compared to placebo, although study did not meet primary endpoint Clinically meaningful improvements observed as compared to placebo across secondary endpoints including BICLA and LLDAS at the mid-dose level in the study Nekt
February 23, 2023	EX-99.1	Phase 2 ISLAND Study of REZPEG in SLE Topline Data Results February 23, 2023 This presentation includes forward - looking statements regarding Nektar’s proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical Exhibit 99.1 Phase 2 ISLAND Study of REZPEG in SLE Topline Data Results February 23, 2023 This presentation includes forward - looking statements regarding Nektar’s proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, unaudited year - end cash and investments and sufficiency of working capital and
February 9, 2023	SC 13G/A	NKTR / Nektar Therapeutics / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 nktra1320923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* Nektar Therapeutics (Name of Issuer) COM (Title of Class of Securities) 640268108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box t
February 9, 2023	SC 13G/A	NKTR / Nektar Therapeutics / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01494-nektartherapeuticscl.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Nektar Therapeutics Class A Title of Class of Securities: Common Stock CUSIP Number: 640268108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate b
February 6, 2023	SC 13G/A	NKTR / Nektar Therapeutics / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Nektar Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
February 2, 2023	SC 13G/A	NKTR / Nektar Therapeutics / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Nektar Therapeutics (Name of Issuer) Common Stock (Title of Class of Securities) 640268108 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
January 23, 2023	SC 13G/A	NKTR / Nektar Therapeutics / BlackRock Inc. Passive Investment SC 13G/A 1 us6402681083012323.txt us6402681083012323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 17) NEKTAR THERAPEUTICS - (Name of Issuer) Common Stock - (Title of Class of Securities) 640268108 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b
January 9, 2023	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numb
December 22, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2022 (December 16, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation)
December 16, 2022	EX-3.1	Amended and Restated Bylaws of Nektar Therapeutics. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF NEKTAR THERAPEUTICS (A DELAWARE CORPORATION) (amended and restated December 15, 2022) ARTICLE I OFFICES SECTION 1. REGISTERED OFFICE. The registered office of the corporation in the State of Delaware shall be as set forth in the Certificate of Incorporation of the corporation, as amended from time to time (the “Certificate of Incorporation”). SECTION 2. O
December 16, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2022 (December 15, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2022 (December 15, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation)
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
November 3, 2022	EX-99.1	Nektar Therapeutics Reports Third Quarter 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2022 Financial Results SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022. Cash and investments in marketable securities on September 30, 2022, were approximately $546.4 million as compared to $628.2 million at the end of the second quart
October 11, 2022	EX-99.1	Nektar Therapeutics (“Nektar”) Rule 2.8 Announcement Exhibit 99.1 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR IMMEDIATE RELEASE 11 October 2022 Nektar Therap
October 11, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2022 NEKTAR THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 11, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Num
October 11, 2022	EX-99.2	PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) Statement regarding termination of discussions with Nektar Therapeutics (“Nektar”) Exhibit 99.2 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION IS NOW CONSIDERED
October 7, 2022	EX-99.1	PureTech Health plc Statement regarding recent press speculation Exhibit 99.1 October 6, 2022 PureTech Health plc Statement regarding recent press speculation PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (?PureTech? or the ?Company?) notes the recent press speculation and confirms that it has exchanged indicative, non-binding proposals with Nektar Therapeutics, Inc. (?Nektar?) regarding a possible combination (which may include, amongst other things, an offer
October 7, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 7, 2022 (October 6, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Co
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKT
August 5, 2022	EX-10.2	Employment Transition, Separation and Consultation Agreement, dated as of June 29, 2022, by and between Nektar Therapeutics and John Northcott.++ Exhibit 10.2 EMPLOYMENT TRANSITION, SEPARATION AND CONSULTATION AGREEMENT This Employment Transition, Separation and Consultation Agreement (this ?Agreement?) is entered into between Nektar Therapeutics, a Delaware corporation, defined to include its affiliated companies (including subsidiaries), employees, officers, directors, managers, agents, and shareholders, successors, assigns, and represent
August 5, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Nektar Therapeutics (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.
August 5, 2022	EX-10.1	Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan Exhibit 10.1 NEKTAR THERAPEUTICS AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN 1.PURPOSE OF PLAN The purpose of this Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan (this ?Plan?) of Nektar Therapeutics, a Delaware corporation (the ?Corporation?), is to promote the success of the Corporation and to increase stockholder value by providing an additional means through t
August 5, 2022	S-8	As filed with the Securities and Exchange Commission on August 5, 2022 As filed with the Securities and Exchange Commission on August 5, 2022 Registration No.
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
August 4, 2022	EX-99.1	Nektar Therapeutics Reports Second Quarter 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports Second Quarter 2022 Financial Results SAN FRANCISCO, August 4, 2022 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2022. Cash and investments in marketable securities at June 30, 2022, were approximately $628.2 million as compared to $798.8 million at December 31, 2021, which is expec
July 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2022 (June 29, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commiss
June 10, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2022 (June 8, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commiss
May 23, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2022 (May 19, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commissi
May 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For th Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEK
May 5, 2022	EX-99.1	Nektar Therapeutics Reports First Quarter 2022 Financial Results Exhibit 99.1 Nektar Therapeutics Reports First Quarter 2022 Financial Results SAN FRANCISCO, May 5, 2022 /PRNewswire/ - Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2022. Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compared to $798.8 million at December 31, 2021, which is expected
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 2, 2022	8-K	Material Impairments, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2022 (April 26, 2022) NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commiss
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 d412608ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 25, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 25, 2022	EX-99.1	Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway into the first half of 2025 Analy Exhibit 99.1 Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook Company focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs Cost restructuring plan results in cash runway into the first half of 2025 Analyst and investor conference call today at 5:00 PM ET (2:00 PM PT) SAN FRANCISCO, April 25, 2022 ? Nektar Therapeutics (Nasdaq: NKTR) today
April 14, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 14, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
April 14, 2022	EX-99.1	Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) Exhibit 99.1 Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) (PRINCETON, N.J., & SAN FRANCISCO, April 14, 2022) - Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegalde
March 14, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2022 NEKTAR THERAPEUTICS (Exact Name of Registrant as Specified in Charter) Delaware 0-24006 94-3134940 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 14, 2022	EX-99.1	Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma Exhibit 99.1 Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma (PRINCETON, N.J., & SAN FRANCISCO, March 14, 2022) - Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) today announced an update following the first a
March 1, 2022	EX-21.1	Subsidiaries of Nektar Therapeutics. Exhibit 21.1 Subsidiaries of Nektar Therapeutics Name Jurisdiction of Incorporation or Organization Inheris Biopharma, Inc. United States
March 1, 2022	EX-10.40	Amendment No. 2 to Strategic Collaboration Agreement dated as of January 12, 2022, by and between Bristol-Myers Squibb and Company and Nektar Therapeutics.+ Exhibit 10.40 [***] Certain confidential portions (indicated by brackets and asterisks) have been omitted from the exhibit in accordance with the rules of the Securities and Exchange Commission. AMENDMENT NO. 2 TO STRATEGIC COLLABORATION AGREEMENT This Amendment No. 2 (this ?Amendment No. 2?) to the Agreement (as defined below) is entered into as of January 12, 2022 (the ?Amendment No. 2 Effective

GB:0UNL	58,15 US$
DE:ITH0	54,94 €

NKTR / Nektar Therapeutics - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings